JPS62277323A - Production of eye drop containing ketotifen fumarate - Google Patents
Production of eye drop containing ketotifen fumarateInfo
- Publication number
- JPS62277323A JPS62277323A JP18799186A JP18799186A JPS62277323A JP S62277323 A JPS62277323 A JP S62277323A JP 18799186 A JP18799186 A JP 18799186A JP 18799186 A JP18799186 A JP 18799186A JP S62277323 A JPS62277323 A JP S62277323A
- Authority
- JP
- Japan
- Prior art keywords
- eye drop
- ketotifen fumarate
- mannitol
- production
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003630 ketotifen fumarate Drugs 0.000 title claims abstract description 9
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000003889 eye drop Substances 0.000 title abstract description 11
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 8
- 239000002997 ophthalmic solution Substances 0.000 claims description 3
- 229940054534 ophthalmic solution Drugs 0.000 claims description 3
- 239000012929 tonicity agent Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 15
- -1 D-erythrose Chemical class 0.000 abstract description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 9
- 235000010355 mannitol Nutrition 0.000 abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 229960000686 benzalkonium chloride Drugs 0.000 abstract description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 150000004043 trisaccharides Chemical class 0.000 abstract description 3
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 abstract description 2
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 abstract description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 abstract description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 239000008101 lactose Substances 0.000 abstract description 2
- 150000002772 monosaccharides Chemical class 0.000 abstract description 2
- 230000002335 preservative effect Effects 0.000 abstract description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 abstract description 2
- 150000004044 tetrasaccharides Chemical class 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 ３、発明の詳細な説明 〔発明の目的〕 本発明は点眼液の製法に関する。[Detailed description of the invention] 3. Detailed description of the invention [Purpose of the invention] The present invention relates to a method for producing eye drops.
一般に、点眼液として具備すべき最も重要な点は、点眼
液が涙液と同程度に等張であることである。そして、点
眼液を等強化するために、通常は塩化ナトリウム等の電
解質が使用されている。Generally, the most important point that an eye drop should have is that it be isotonic to the same extent as lachrymal fluid. Electrolytes such as sodium chloride are commonly used to strengthen eye drops.
ところで、フマル酸ケトチフエンは経口喘息治療剤であ
るが、点眼剤としても有用なことが報告されている（王
国ら、病院薬学、１０巻、３号、１７１〜１７６貞、１
９８４年）。By the way, ketotifen fumarate is an oral asthma treatment agent, but it has also been reported that it is also useful as an eye drop (King et al., Hospital Pharmacy, Vol. 10, No. 3, 171-176 Tei, 1).
984).
しかしながら、フマル酸ケトチフエンはそれ単独では点
眼液として不適であり、等張化剤を必要とする。しかる
に等張化剤として通常使用されている電解質を使用する
と経時安定性が著しく損なわれることが判明した。However, ketotifen fumarate alone is unsuitable as an eye drop and requires a tonicity agent. However, it has been found that the use of commonly used electrolytes as tonicity agents significantly impairs stability over time.
そこで、本発明者らはこの欠点を改良すべく、鋭意研究
した結果、フマル酸ケトチフエン含有の安定な点眼液の
製法を見出して本発明を完成した。In order to improve this drawback, the present inventors conducted intensive research and found a method for producing a stable ophthalmic solution containing ketotifen fumarate, thereby completing the present invention.
本発明は、等張化剤として多価アルコール類を使用、す
ることからなる、フマル酸ケトチフエン含有点眼液の製
法に関する。The present invention relates to a method for producing an ophthalmic solution containing ketotifen fumarate, which comprises using polyhydric alcohols as a tonicity agent.
本発明に使用される多価アルコール類としては、例えば
グリセリン、プロピレングリコール、トリメチレングリ
コール、ペンタエリトリトール、ポリエチレングリコー
ルなどの二以上の水酸基を有するアルコール類の他に更
に、Ｄ−エリトロース ｌ） −１Ｊボース、Ｄ−キシ
ロース、Ｄ−グルコース、Ｄ−マンノース、Ｄ−フルク
トース、Ｌ−ラムノースのような単糖類、スクロース、
マルトース、ラクトース等の三糖類、ラフィノース等の
三糖類、スタキオース等の四糖類のような少糖類からな
る糖類、エリトリトール、キシリトール、Ｄ−マンニト
ールのヨウな糖アルコール類をあげることができる。Examples of the polyhydric alcohols used in the present invention include alcohols having two or more hydroxyl groups such as glycerin, propylene glycol, trimethylene glycol, pentaerythritol, and polyethylene glycol, as well as D-erythrose l) -1J Monosaccharides such as bose, D-xylose, D-glucose, D-mannose, D-fructose, L-rhamnose, sucrose,
Saccharides consisting of oligosaccharides such as trisaccharides such as maltose and lactose, trisaccharides such as raffinose, and tetrasaccharides such as stachyose, and other sugar alcohols such as erythritol, xylitol, and D-mannitol can be mentioned.
多価アルコール類の添加量は、等強化に必要な量であり
、使用されろ多価アルコールの種類により異なる。The amount of polyhydric alcohol added is the amount necessary for equal reinforcement, and varies depending on the type of polyhydric alcohol used.
本発明においては、常法に従い塩化ベンザルコニウムの
ような防腐剤を適宜使用することができる。In the present invention, a preservative such as benzalkonium chloride can be appropriately used according to a conventional method.
本発明の点眼液は常法により製造される。例えばフマル
酸ケトチフエン、多価アルコール類および必要に応じて
防腐剤を水に俗解する。得られた浴液に例えは水酸化ナ
トリウムのような塩基を加えて好適なｐＨに調整した後
、無菌ｒ過し、無菌容器に小分することによって得られ
る。The eye drops of the present invention are manufactured by conventional methods. For example, ketotifen fumarate, polyhydric alcohols and, if necessary, preservatives are added to water. For example, a base such as sodium hydroxide is added to the obtained bath solution to adjust the pH to a suitable value, followed by sterile filtration and aliquoting into sterile containers.
次に実施例をあげて本発明を更に詳細に説明する。 Next, the present invention will be explained in more detail with reference to Examples.
実施例１゜
フマル酸ケトチフエン１．０ノ、塩化ベンザルコニウム
０．１ｇおよびマンニトール５０ノを注用蒸留水約８０
０１１／に俗解した。次いで水酸化ナトリウムを適量加
えてｐＨを５．０に調整した後、全量がＩＱＯＯｇ／と
なるように性用蒸留水を加えた。Example 1 1.0 g of ketotiphene fumarate, 0.1 g of benzalkonium chloride and 50 g of mannitol were added to about 80 g of distilled water.
It was commonly understood in 011/. Next, an appropriate amount of sodium hydroxide was added to adjust the pH to 5.0, and then distilled water was added so that the total amount was IQOOg/.
実施例り
実施例１において、マンニトール５０ノの代りにブドウ
糖６０ｆを用いて、以下同様に実施した。EXAMPLE The same procedure as in Example 1 was carried out except that 60 f of glucose was used instead of 50 g of mannitol.
実施例λ
実施例１において、Ｄ−マンニトール５ｏｆの代りにグ
リセリン２５ノを用いて、以下同様に実施した。Example λ The same procedure as in Example 1 was carried out except that 25 parts of glycerin was used instead of 5 parts of D-mannitol.
実施例４゜
実施例１において、Ｄ−マンニトール５０ｙの代りにプ
ロピレングリコール２１ノヲ用いて、以下同様に実施し
た。Example 4 The same procedure as in Example 1 was repeated except that 21 y of propylene glycol was used instead of 50 y of D-mannitol.
実施例５゜
実施例１において、Ｄ−マンニトール５ａｙｃｖ代りに
ポリエチレングリコール２００の５０１を用いて、以下
同様に実施した。Example 5 The same procedure as in Example 1 was repeated except that polyethylene glycol 200 501 was used instead of D-mannitol 5aycv.
実施例６゜
実施例１において、Ｄ−マンニトール５０ｙの代りにポ
リエチレングリコール４００の１００ｙを用いて、以下
同様に実施した。Example 6 The same procedure as in Example 1 was repeated except that 100 y of polyethylene glycol 400 was used instead of 50 y of D-mannitol.
比較例１゜
実施例１において、マンニトール５０ｆの代りに塩化ナ
トリウム１０１を用いて、以下同様に実施した。Comparative Example 1 The same procedure as in Example 1 was repeated except that sodium chloride 101 was used instead of mannitol 50f.
比較例２〜６゜ 種々の電解質を用いて、比較例１と同様に実施した。Comparative example 2~6° It was carried out in the same manner as Comparative Example 1 using various electrolytes.
試験例
実施例１乃至６、比較例１乃至６で得られた点眼液を２
ｍｌアンプルに充填した後、１００’（：で８時間後
および１６時間後の経時変化を測定した。Test Examples The eye drops obtained in Examples 1 to 6 and Comparative Examples 1 to 6 were
After filling into a ml ampoule, changes over time were measured at 100' (:) after 8 hours and 16 hours.
結果を表１に示す。The results are shown in Table 1.
表１から明らかの如く、多１１．ｌｌ１ｉアルコール類
を添加した場合は、電解質を添加した場合に比べてフマ
ル酸ケトチフエンは安定であった。As is clear from Table 1, 11. Ketothiphene fumarate was more stable when ll1i alcohols were added than when an electrolyte was added.
Claims (1)
とするフマル酸ケトチフエン含有点眼液の製法。A method for producing an ophthalmic solution containing ketotifen fumarate, characterized by using a polyhydric alcohol as a tonicity agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3447686 | 1986-02-19 | ||
| JP61-34476 | 1986-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62277323A true JPS62277323A (en) | 1987-12-02 |
Family
ID=12415301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18799186A Pending JPS62277323A (en) | 1986-02-19 | 1986-08-11 | Production of eye drop containing ketotifen fumarate |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62277323A (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0273014A (en) * | 1988-07-15 | 1990-03-13 | Lab Cusi Sa | Production of ophthalmic alpha-methyl-4-(2'- thienylcarbonyl) phenylacetate lysin liquid agent |
| WO1991001718A1 (en) * | 1989-08-03 | 1991-02-21 | Eisai Co., Ltd. | Method of photostabilizing eyewash and photostabilized eyewash |
| FR2679773A1 (en) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Ophthalmic preparation containing an acceptable antimicrobial osmotic agent |
| FR2734159A1 (en) * | 1995-05-17 | 1996-11-22 | Nicolas Francois Michel | Compsn. to treat external eye ailments based on sugar, pref. sucrose |
| WO1997013517A1 (en) * | 1995-10-09 | 1997-04-17 | Santen Pharmaceutical Co., Ltd. | Aqueous eye drops containing apafant as principal agent |
| WO1998047510A1 (en) * | 1997-04-24 | 1998-10-29 | Taisho Pharmaceutical Co., Ltd. | Eye drops |
| US5952387A (en) * | 1995-08-04 | 1999-09-14 | Hokuriku Seiyaku Co., Ltd. | Photostable aqueous solution containing benzyl alcohol derivatives |
| JP2001158750A (en) * | 1999-12-02 | 2001-06-12 | Lion Corp | Method for improving sustainability of ophthalmic composition and anti-allergic medicine |
| FR2802414A1 (en) * | 1999-12-20 | 2001-06-22 | G Pharm Lab | Compositions containing raffinose or stachyose together with a saponin or arginine, have anti-allergic and anti-inflammatory activity, for the treatment of asthma, eczema, arthroses, and the like |
| WO2001047521A1 (en) * | 1999-12-23 | 2001-07-05 | Novartis Ag | Use of ketotifen as ophthalmic agent |
| EP1172098A1 (en) * | 1998-01-15 | 2002-01-16 | Novartis AG | Pharmaceutical compositions comprising ketotifen |
| JP2002047118A (en) * | 2000-05-22 | 2002-02-12 | Kuraray Co Ltd | Antibacterial composition |
| EP1285947A1 (en) * | 2000-05-22 | 2003-02-26 | Kuraray Co., Ltd. | Antimicrobial composition |
| WO2004022063A1 (en) * | 2002-09-09 | 2004-03-18 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
| US6774137B2 (en) | 1999-07-23 | 2004-08-10 | Novartis Ag | Ophthalmic composition |
| JP2006316055A (en) * | 2005-04-14 | 2006-11-24 | Taisho Pharmaceut Co Ltd | Liquid for external use |
| EP1845983A4 (en) * | 2004-10-25 | 2008-03-12 | Bausch & Lomb | Ophthalmic compositions and methods of using the same |
| CN100389770C (en) * | 2002-09-09 | 2008-05-28 | 参天制药株式会社 | Transparent eye drops containing latanoprost |
| JP2011021003A (en) * | 2009-06-16 | 2011-02-03 | Rohto Pharmaceutical Co Ltd | Aqueous composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56150012A (en) * | 1980-03-21 | 1981-11-20 | Wellcome Found | Isotomic solution medicine |
-
1986
- 1986-08-11 JP JP18799186A patent/JPS62277323A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56150012A (en) * | 1980-03-21 | 1981-11-20 | Wellcome Found | Isotomic solution medicine |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0273014A (en) * | 1988-07-15 | 1990-03-13 | Lab Cusi Sa | Production of ophthalmic alpha-methyl-4-(2'- thienylcarbonyl) phenylacetate lysin liquid agent |
| WO1991001718A1 (en) * | 1989-08-03 | 1991-02-21 | Eisai Co., Ltd. | Method of photostabilizing eyewash and photostabilized eyewash |
| FR2679773A1 (en) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Ophthalmic preparation containing an acceptable antimicrobial osmotic agent |
| WO1993002663A1 (en) * | 1991-07-30 | 1993-02-18 | Laboratoires Merck Sharp & Dohme-Chibret | Ophthalmic compositions based on polyhydric alcohols |
| FR2734159A1 (en) * | 1995-05-17 | 1996-11-22 | Nicolas Francois Michel | Compsn. to treat external eye ailments based on sugar, pref. sucrose |
| US5952387A (en) * | 1995-08-04 | 1999-09-14 | Hokuriku Seiyaku Co., Ltd. | Photostable aqueous solution containing benzyl alcohol derivatives |
| US6162833A (en) * | 1995-08-04 | 2000-12-19 | Hokuriku Seiyaku Co., Ltd. | Photostable aqueous solution comprising benzyl alcohol derivatives |
| WO1997013517A1 (en) * | 1995-10-09 | 1997-04-17 | Santen Pharmaceutical Co., Ltd. | Aqueous eye drops containing apafant as principal agent |
| US6015810A (en) * | 1995-10-09 | 2000-01-18 | Santen Pharmaceutical Co., Ltd. | Aqueous ophthalmic solution containing apafant as active ingredient |
| CN1103217C (en) * | 1995-10-09 | 2003-03-19 | 参天制药株式会社 | Aqueous eye drops contg. apafant as principal agent |
| WO1998047510A1 (en) * | 1997-04-24 | 1998-10-29 | Taisho Pharmaceutical Co., Ltd. | Eye drops |
| US6468548B1 (en) | 1998-01-15 | 2002-10-22 | Novartis Ag | Autoclavable pharmaceutical compositions containing a chelating agent |
| EP1172098A1 (en) * | 1998-01-15 | 2002-01-16 | Novartis AG | Pharmaceutical compositions comprising ketotifen |
| EP2281554A1 (en) * | 1998-01-15 | 2011-02-09 | Novartis AG | Eye drop composition comprising ketotifen |
| US6776982B2 (en) | 1998-01-15 | 2004-08-17 | Novartis Ag | Autoclavable pharmaceutical compositions containing a chelating agent |
| CZ300614B6 (en) * | 1999-07-23 | 2009-07-01 | Novartis Ag | Ophthalmic composition containing ketotifen |
| US6774137B2 (en) | 1999-07-23 | 2004-08-10 | Novartis Ag | Ophthalmic composition |
| US6777429B1 (en) | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
| JP2001158750A (en) * | 1999-12-02 | 2001-06-12 | Lion Corp | Method for improving sustainability of ophthalmic composition and anti-allergic medicine |
| FR2802414A1 (en) * | 1999-12-20 | 2001-06-22 | G Pharm Lab | Compositions containing raffinose or stachyose together with a saponin or arginine, have anti-allergic and anti-inflammatory activity, for the treatment of asthma, eczema, arthroses, and the like |
| WO2001047521A1 (en) * | 1999-12-23 | 2001-07-05 | Novartis Ag | Use of ketotifen as ophthalmic agent |
| EP1285947A1 (en) * | 2000-05-22 | 2003-02-26 | Kuraray Co., Ltd. | Antimicrobial composition |
| EP1285947A4 (en) * | 2000-05-22 | 2005-04-13 | Kuraray Co | Antimicrobial composition |
| JP2002047118A (en) * | 2000-05-22 | 2002-02-12 | Kuraray Co Ltd | Antibacterial composition |
| WO2004022063A1 (en) * | 2002-09-09 | 2004-03-18 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
| CN100389770C (en) * | 2002-09-09 | 2008-05-28 | 参天制药株式会社 | Transparent eye drops containing latanoprost |
| JP2009102373A (en) * | 2002-09-09 | 2009-05-14 | Santen Pharmaceut Co Ltd | Transparent eye drop containing latanoprost as active ingredient |
| US8143312B2 (en) | 2002-09-09 | 2012-03-27 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
| JP2012062324A (en) * | 2002-09-09 | 2012-03-29 | Santen Pharmaceut Co Ltd | Clear eye drop liquid using latanoprost as active ingredient |
| US8183291B2 (en) | 2002-09-09 | 2012-05-22 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
| KR101253941B1 (en) * | 2002-09-09 | 2013-04-16 | 산텐 세이야꾸 가부시키가이샤 | Transparent eye drops containing latanoprost |
| JP2008517937A (en) * | 2004-10-25 | 2008-05-29 | ボーシュ アンド ローム インコーポレイティド | Ophthalmic composition and method of use thereof |
| EP1845983A4 (en) * | 2004-10-25 | 2008-03-12 | Bausch & Lomb | Ophthalmic compositions and methods of using the same |
| JP2006316055A (en) * | 2005-04-14 | 2006-11-24 | Taisho Pharmaceut Co Ltd | Liquid for external use |
| JP2011021003A (en) * | 2009-06-16 | 2011-02-03 | Rohto Pharmaceutical Co Ltd | Aqueous composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62277323A (en) | Production of eye drop containing ketotifen fumarate | |
| EP0639070B1 (en) | Use of borate-polyol complexes in ophthalmic compositions | |
| US5422116A (en) | Liquid ophthalmic sustained release delivery system | |
| US6365636B1 (en) | Use of borate-polyol complexes in ophthalmic compositions | |
| USRE43583E1 (en) | Ophthalmic composition for soft contact lens comprising terpenoid | |
| US4136177A (en) | Xanthan gum therapeutic compositions | |
| EP1649860B1 (en) | Pharmaceutical composition for ophthalmic use | |
| EP0799615A1 (en) | Liposome eye drops | |
| KR970705932A (en) | Chewing gum filled with juice in the center (FRUIT JUICE CENTER-FILLED CHEWING GUM) | |
| JP2006232822A (en) | Pranoprofen-containing composition | |
| EP1623722B1 (en) | Composition for ophthalmic use | |
| EP2123278A1 (en) | Eye drop reparation comprising latanoprost | |
| JP2006232823A (en) | Pranoprofen-containing composition | |
| KR101322527B1 (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
| EP1480677B1 (en) | Composition for stabilizing hyaluronic acid | |
| JP4831944B2 (en) | Planoprofen-containing composition | |
| US5182102A (en) | Anti-glaucoma compositions | |
| AU661186B2 (en) | Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis | |
| EP0069075B1 (en) | Pharmaceutical preparation for treating glaucoma and ocular hypertension | |
| GIFFORD | REACTION OF BUFFER SOLUTION AND OF OPHTHALMIC DRUGS: A FURTHER NOTE | |
| JP4756837B2 (en) | Planoprofen-containing composition | |
| JP2002104971A (en) | Ophthalmic composition | |
| JP2011137039A (en) | Composition containing pranoprofen | |
| PARK et al. | Preoperative Maximal Mydriasis Test in Cataract Patients | |
| Brásio | Mgr Manuel Nunes Gabriel évêque de Malanje—(5-XII-l 957) |